Estimated direct costs of non‐small cell lung cancer by stage at diagnosis and disease management phase: A whole‐disease model-Reference-Cited by-同舟云学术

Estimated direct costs of non‐small cell lung cancer by stage at diagnosis and disease management phase: A whole‐disease model

Published:2020-11-21 Issue:1 Volume:12 Page:13-20
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Buja Alessandra¹^ORCID,Rivera Michele¹,De Polo Anna¹,Brino Eugenio di²,Marchetti Marco²,Scioni Manuela³,Pasello Giulia⁴,Bortolami Alberto⁵,Rebba Vincenzo⁶,Schiavon Marco¹,Calabrese Fiorella¹,Mandoliti Giovanni⁷,Baldo Vincenzo¹,Conte PierFranco⁴⁸

Affiliation:

1. Department of Cardiologic, Vascular, and Thoracic Sciences and Public Health University of Padua Padua Italy

2. Istituto Superiore di Sanità Rome Italy

3. Statistics Department University of Padua Padua Italy

4. Medical Oncology 2 Istituto Oncologico Veneto IRCCS Padova Italy

5. Rete Oncologica Veneta, Istituto Oncologico Veneto Padova Italy

6. “Marco Fanno” Department of Economics and Management University of Padua Padua Italy

7. U.O.C. Radioterapia oncologica Ospedale Santa Maria della Misericordia, AULSS 5 “Polesana” Rovigo Italy

8. Department of Surgery, Oncology and Gastroenterology University of Padova Padova Italy

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13616

Reference62 articles.

1. Lung Cancer Statistics

2. Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey

3. Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer

4. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

5. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Facing an un-met need in lung cancer screening: The never smokers;Critical Reviews in Oncology/Hematology;2024-10

2. Cancers attributable to tobacco smoking in Italy in 2020;Cancer Epidemiology;2024-10

3. Advancing early access policies for innovative cancer drugs: a scoping review and explorative analysis in the Italian setting;Journal of Pharmaceutical Policy and Practice;2024-07-15

4. New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe;The Lancet Regional Health - Europe;2024-03

5. Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process;Current Oncology;2023-12-06